Combined targeted therapy with dabraphenib +trametinib in treatment of melanoma patients with V600 BRAF mutations and brain metastases
- Authors: Naskhletashvili D.R1, Gorbunova V.A1, Bekyashev A.K.1, Demidov L.V1, Kharkevich G.Y.1, Samoylenko I.V1, Baryshnikov K.A1, Orlova K.V1, Utyashev I.A1, Petenko N.N1, Markina I.G1, Moskvina E.A1
-
Affiliations:
- FSBI RORC n.a. N.N. Blokhin of RMH
- Issue: No 8 (2017)
- Pages: 76-80
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289858
- ID: 289858
Cite item
Abstract
Keywords
Full Text
About the authors
D. R Naskhletashvili
FSBI RORC n.a. N.N. Blokhin of RMH
Email: nas-david@yandex.ru
PhD, Senior Researcher at the Neurosurgical (Oncological) Department
V. A Gorbunova
FSBI RORC n.a. N.N. Blokhin of RMH
A. Kh Bekyashev
FSBI RORC n.a. N.N. Blokhin of RMH
L. V Demidov
FSBI RORC n.a. N.N. Blokhin of RMH
G. Yu Kharkevich
FSBI RORC n.a. N.N. Blokhin of RMH
I. V Samoylenko
FSBI RORC n.a. N.N. Blokhin of RMH
K. A Baryshnikov
FSBI RORC n.a. N.N. Blokhin of RMH
K. V Orlova
FSBI RORC n.a. N.N. Blokhin of RMH
I. A Utyashev
FSBI RORC n.a. N.N. Blokhin of RMH
N. N Petenko
FSBI RORC n.a. N.N. Blokhin of RMH
I. G Markina
FSBI RORC n.a. N.N. Blokhin of RMH
E. A Moskvina
FSBI RORC n.a. N.N. Blokhin of RMH
References
- Schouten L.]., Rutten J., Huveneers H.a., Twijnstra А. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698-705.
- Tabouret E., Chinot О., Metellus P., Tallet А., Viens P., Gonçalves А. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012;32:4655-62.
- Fife K., Colman M., Stevens G., et al. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 2004;22:1293-300.
- Davies M., Liu P., McIntyre S., Kim K.B., Papadopoulos N., Hwu W.]., Hwu P., Bedikian A. литература Prognostic factors for survival in melanoma patients with bran metastases. Cancer. 2011;117:1687-96.
- Eigentler T., Figl A., Krex D., Mohr P., Mauch C., Rass K., Bostroem A., Heese О., Koelbl О., Garbe C., Schadendorf D. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117:1697-703.
- Bezjak A., Adam J., Barton R., Panzarella T., Laperriere N., Wong C.S., Mason W., Buckley C., Levin W., McLean M., Wu J.S., Sia M., Kirkbride P. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J. Cancer. 2002;38:487-96.
- Khuntia D., Brown P., Li J., Mehta M.P. Whole-brain radiotherapy in the management of brain metastasis. J. Clin. Oncol. 2006;24:1295-304.
- Tsao M.N., Lloyd N., Wong R., Chow E., Rakovitch E., Laperriere N., Xu W., Sahgal A. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst. Rev. 2006;3:CD003869.
- Agarwala S., Kirkwood J., Gore M., Dreno B., Thatcher N., Czarnetski B., Atkins M., Buzaid A., Skarlos D., Rankin E.M. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase Il study. J. Clin. Oncol. 2004;22:2101-107.
- Atkins M., Sosman J., Agarwala S., Logan T., Clark J., Ernstoff M.S., Lawson D., Dutcher J.P., Weiss G., Curti В., Margolin K.A. Temozolomide, thalidomide and whole brain radiation therapy for patients with brain metastatses from metastatic melanoma: a phase ll Cytokine Working Group study Cancer. 2008;113:2139-45.
- Margolin K., Atkins В., Thompson A., Ernstoff S., Weber J., Flaherty L., Clark l., Weiss G., Sosman J., II Smith W., Dutcher P., Gollob J., Longmate J., Johnson D. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase ll trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 2002;128:214-18.
- Mornex F., Thomas L., Mohr P, et al. A prospective randomized multicenter phase Ill trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 2003;13:97-103.
- Long G.V., Margolin K.A. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. Am. Soc. Clin. Oncol. Educ. Book. 2013;33: 393-98.
- Jakob J.A., Bassett R.L.Jr, Ng C.S., Curry J.L, Joseph R.W., Alvarado G.C., Rohlfs M.L., Richard J., Gershenwald J.E., Kim K.B., Lazar A.J., Hwu P., Davies M.A. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118:4014-23.
- Kefford R., Malo М., Arance A., et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open label, single arm, phase 2, multicenter study. Paper presented at: 2O13 Society for Melanoma Research Congress; November 17-2O, 2O13;Philadelphia, PA.
- Dummer R., Goldinger S., Turtschietal C. Vemurafenib in patients with BRAF-V6OO mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. Eur. J. Cancer. 2014;50:611-21.
- Gibney G., Marynchenko M., Ayas C., et al. Treatment patterns and outcome in BRAF V6OOE mutant melanoma patients with brain metastases receiving vemurafenib in the real world setting. ln: 2014 ASCO Annual Meeting.
- Falchook G.S., Long G.V., Kurzrock R., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893-901.
- Long G.V., Trefzer U., Davies M.A., et al. Dabrafenib in patients with Val6OOGlu or Val6OOLys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet. Oncol. 2012;13:1087-95.
- Berghoff A.S., Preusser М. The future of targeted therapies for brain metastases. Future Oncol. 2015;11:2315-27.
- Venur V.A., Ahluwalia M.S. Targeted Therapy in Brain Metastases: Ready for Primetime? 2016 ASCO Educational BOOK, e123-30.